BIOATLA, INC. Operating Expenses
BIOATLA, INC. (BCAB) reported Operating Expenses of $6.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- BIOATLA, INC. operating expenses for the quarter ending 2026-06-30 was $6.27M, a 66.36% decline year-over-year.
- BIOATLA, INC. operating expenses for the quarter ending 2026-03-31 was $9.31M, a 47.16% decline year-over-year.
- BIOATLA, INC. operating expenses for the quarter ending 2025-12-31 was $11.26M, a 30.71% decline year-over-year.
- BIOATLA, INC. operating expenses for the quarter ending 2025-09-30 was $13.79M, a 38.08% decline year-over-year.
- BIOATLA, INC. operating expenses for fiscal 2025 was $61.30M, a 27.83% decline from fiscal 2024.
- BIOATLA, INC. operating expenses for fiscal 2024 was $84.94M, a 34.50% decline from fiscal 2023.
- BIOATLA, INC. operating expenses for fiscal 2023 was $129.69M, a 19.93% increase from fiscal 2022.
- BIOATLA, INC. operating expenses for fiscal 2022 was $108.14M, a 11.84% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.27M 10-Q · filed 2026-08-13 | $15.58M 10-Q · filed 2026-08-13 | $26.84M derived: sum of 3 quarters · filed 2026-08-13 | $40.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $9.31M 10-Q · filed 2026-05-15 | $20.56M derived: sum of 2 quarters · filed 2026-05-15 | $34.35M derived: sum of 3 quarters · filed 2026-05-15 | $53.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $11.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $25.04M derived: sum of 2 quarters · filed 2026-03-31 | $43.69M derived: sum of 3 quarters · filed 2026-08-13 | $61.30M 10-K · filed 2026-03-31 |
| 2025-09-30 | $13.79M 10-Q · filed 2025-11-13 | $32.44M derived: sum of 2 quarters · filed 2026-08-13 | $50.05M 10-Q · filed 2025-11-13 | $66.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $18.65M 10-Q · filed 2026-08-13 | $36.26M 10-Q · filed 2026-08-13 | $52.51M derived: sum of 3 quarters · filed 2026-08-13 | $74.78M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $17.61M 10-Q · filed 2026-05-15 | $33.86M derived: sum of 2 quarters · filed 2026-05-15 | $56.13M derived: sum of 3 quarters · filed 2026-05-15 | $78.10M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $16.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $38.51M derived: sum of 2 quarters · filed 2026-03-31 | $60.49M derived: sum of 3 quarters · filed 2026-03-31 | $84.94M 10-K · filed 2026-03-31 |
| 2024-09-30 | $22.27M 10-Q · filed 2025-11-13 | $44.24M derived: sum of 2 quarters · filed 2025-11-13 | $68.70M 10-Q · filed 2025-11-13 | $97.23M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $21.97M 10-Q · filed 2025-08-07 | $46.43M 10-Q · filed 2025-08-07 | $74.97M derived: sum of 3 quarters · filed 2025-08-07 | $109.98M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $24.46M 10-Q · filed 2025-05-06 | $52.99M derived: sum of 2 quarters · filed 2025-05-06 | $88.01M derived: sum of 3 quarters · filed 2025-05-06 | $125.21M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $28.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $63.56M derived: sum of 2 quarters · filed 2025-03-28 | $100.76M derived: sum of 3 quarters · filed 2025-03-28 | $129.69M 10-K · filed 2025-03-28 |
| 2023-09-30 | $35.02M 10-Q · filed 2024-11-07 | $72.22M derived: sum of 2 quarters · filed 2024-11-07 | $101.15M 10-Q · filed 2024-11-07 | $129.71M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $37.20M 10-Q · filed 2024-08-08 | $66.13M 10-Q · filed 2024-08-08 | $94.69M derived: sum of 3 quarters · filed 2024-08-08 | $120.87M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $28.93M 10-Q · filed 2024-05-14 | $57.49M derived: sum of 2 quarters · filed 2024-05-14 | $83.67M derived: sum of 3 quarters · filed 2024-05-14 | $112.72M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $28.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $54.74M derived: sum of 2 quarters · filed 2024-03-26 | $83.79M derived: sum of 3 quarters · filed 2024-03-26 | $108.14M 10-K · filed 2024-03-26 |
| 2022-09-30 | $26.18M 10-Q · filed 2023-11-07 | $55.23M derived: sum of 2 quarters · filed 2023-11-07 | $79.58M 10-Q · filed 2023-11-07 | $103.07M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $29.05M 10-Q · filed 2023-08-01 | $53.40M 10-Q · filed 2023-08-01 | $76.89M derived: sum of 3 quarters · filed 2023-08-01 | $100.58M derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-03-31 | $24.35M 10-Q · filed 2023-05-11 | $47.83M derived: sum of 2 quarters · filed 2023-05-11 | $71.53M derived: sum of 3 quarters · filed 2023-05-11 | $102.24M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $23.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $47.18M derived: sum of 2 quarters · filed 2023-03-23 | $77.89M derived: sum of 3 quarters · filed 2023-03-23 | $96.69M 10-K · filed 2023-03-23 |
| 2021-09-30 | $23.70M 10-Q · filed 2022-11-04 | $54.41M derived: sum of 2 quarters · filed 2022-11-04 | $73.20M 10-Q · filed 2022-11-04 | $89.66M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $30.71M 10-Q · filed 2022-08-09 | $49.51M 10-Q · filed 2022-08-09 | $65.96M derived: sum of 3 quarters · filed 2022-08-09 | $74.13M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $18.80M 10-Q · filed 2022-05-05 | $35.25M derived: sum of 2 quarters · filed 2022-05-05 | $43.42M derived: sum of 3 quarters · filed 2022-05-05 | $48.13M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $16.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $24.62M derived: sum of 2 quarters · filed 2022-02-28 | $29.33M derived: sum of 3 quarters · filed 2022-02-28 | $30.53M 10-K · filed 2022-02-28 |
| 2020-09-30 | $8.16M 10-Q · filed 2021-11-15 | $12.88M derived: sum of 2 quarters · filed 2021-11-15 | $14.07M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $4.71M 10-Q · filed 2021-08-13 | $5.91M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $1.20M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $33.47M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |